NEW YORK (TheStreet) -- RATINGS CHANGES
Halozyme Therapeutics (HALO) was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.
Hewlett-Packard (HPQ - Get Report) was upgraded at Goldman Sachs to neutral from sell. Management has executed far more effectively than anticipated, Goldman Sachs said. Twelve-month price target is $32.
Immunogen (IMGN - Get Report) was upgraded at UBS to neutral from sell. Bullish outlook on Kadcyla and royalty revenue providing lower-risk valuation support, UBS said. Twelve-month price target is $13.(PCOM) was downgraded to hold at TheStreet Ratings. Phoenix Companies (PNX) was upgraded to hold at TheStreet Ratings. Springleaf (LEAF) was downgraded at Sterne Agee to neutral. Twelve-month price target is $28. Estimates were also cut, because of weakness in two units, Sterne Agee said. Sprouts (SFM) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $34. Pullback provides an opportunity, Credit Suisse said. Twelve-month price target is $34. Triumph (TGI) was upgraded at Credit Suisse to outperform from neutral. Company offers growth at a reasonable price, Credit Suisse said. Twelve-month price target is $88. (THRX) was downgraded at Robert Baird to hold from buy. Valuation call, following the recent split, Robert Baird said. Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here. Follow TheStreet on Twitter and become a fan on Facebook. Kass: Turn, Turn, Turn
Why Amazon Loves Local, and Why It Absolutely Shouldn't
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts